RecruitingNCT05652348

Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer


Sponsor

Technische Universität Dresden

Enrollment

48 participants

Start Date

Dec 8, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Patients with gastric or colon cancer with peritoneal carcinomatosis will receive a biopsy of the tumor during their primary curative surgery. The operation is performed according to standard and includes resection of the primary tumor and any metastases and followed by HIPEC (Intraperitoneal hyperthermic chemoperfusion) according to the respective hospital standard. Organoid cultures from the biopsies are established in the research laboratory. Various chemotherapeutic agents are tested on these tumor organoids in the laboratory and the tumor organoids are analyzed in detail with regard to genetic alterations in order to find alterations that can be addressed, if necessary, by means of targeted drugs against peritoneal carcinomatosis.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study develops a method to predict whether patients with stomach or colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis) will respond to heated chemotherapy delivered directly into the abdomen during surgery (HIPEC). **You may be eligible if...** - You have stomach cancer (including gastroesophageal junction) or colon/rectal cancer that has spread to the peritoneum (lining of the abdomen) - This spread is confirmed during surgery - You are a candidate for HIPEC surgery **You may NOT be eligible if...** - Your cancer has spread to other distant organs beyond the peritoneum - You are not a surgical candidate due to health reasons Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEREstablishment of organoid cultures and in vitro sensitivity testing

Generating patient-derived tumor organoid models as well as orthotopic mouse models from peritoneal carcinomatosis lesions and to investigate their response to different therapies.


Locations(2)

Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustv Carus Dresden

Dresden, Germany

University Hospital Heidelberg

Heidelberg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05652348


Related Trials